- Home
- CHN vs NVCT Comparison
CHN vs NVCT Comparison
Compare CHN & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- NVCT
- Stock Information
- Founded
- CHN 1992
- NVCT 2020
- Country
- CHN United States
- NVCT United States
- Employees
- CHN N/A
- NVCT N/A
- Industry
- CHN Investment Managers
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- CHN Finance
- NVCT Health Care
- Exchange
- CHN Nasdaq
- NVCT Nasdaq
- Market Cap
- CHN 153.9M
- NVCT 152.3M
- IPO Year
- CHN N/A
- NVCT 2022
- Fundamental
- Price
- CHN $15.87
- NVCT $6.00
- Analyst Decision
- CHN
- NVCT Strong Buy
- Analyst Count
- CHN 0
- NVCT 3
- Target Price
- CHN N/A
- NVCT $15.33
- AVG Volume (30 Days)
- CHN 31.8K
- NVCT 233.1K
- Earning Date
- CHN 01-01-0001
- NVCT 08-05-2025
- Dividend Yield
- CHN 0.19%
- NVCT N/A
- EPS Growth
- CHN N/A
- NVCT N/A
- EPS
- CHN N/A
- NVCT N/A
- Revenue
- CHN N/A
- NVCT N/A
- Revenue This Year
- CHN N/A
- NVCT N/A
- Revenue Next Year
- CHN N/A
- NVCT N/A
- P/E Ratio
- CHN N/A
- NVCT N/A
- Revenue Growth
- CHN N/A
- NVCT N/A
- 52 Week Low
- CHN $9.00
- NVCT $4.44
- 52 Week High
- CHN $12.98
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- CHN 64.58
- NVCT 27.10
- Support Level
- CHN $15.40
- NVCT $6.30
- Resistance Level
- CHN $16.06
- NVCT $7.38
- Average True Range (ATR)
- CHN 0.20
- NVCT 0.48
- MACD
- CHN -0.07
- NVCT -0.15
- Stochastic Oscillator
- CHN 46.53
- NVCT 6.28
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.